These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24563371)

  • 1. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
    Liu LL; Zhang MF; Pan YH; Yun JP; Zhang CZ
    Tumour Biol; 2014 Mar; 35(3):1763-74. PubMed ID: 24563371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
    Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
    Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
    Personeni N; Rimassa L; Pressiani T; Destro A; Ligorio C; Tronconi MC; Bozzarelli S; Carnaghi C; Di Tommaso L; Giordano L; Roncalli M; Santoro A
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1179-87. PubMed ID: 23568548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
    Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
    Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
    Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
    Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
    Palmer DH; Hussain SA; Smith AJ; Hargreaves S; Ma YT; Hull D; Johnson PJ; Ross PJ
    Br J Cancer; 2013 Aug; 109(4):888-90. PubMed ID: 23880824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
    Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
    Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Shoji H; Yoshio S; Mano Y; Doi H; Sugiyama M; Osawa Y; Kimura K; Arai T; Itokawa N; Atsukawa M; Aoki Y; Fukai M; Taketomi A; Mizokami M; Kanto T
    Int J Cancer; 2017 Sep; 141(5):1011-1017. PubMed ID: 28555943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
    HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
    Cao G; Li X; Qin C; Li J
    Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
    Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
    Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
    PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.